Q-omics provides the consensus-scored ARR3 profile across patient tissues and cancer cell-line models. ARR3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARR3 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, ARR3 RNA expression shows 17,670 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where ARR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARR3 survival associations across molecular data types. ARR3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARR3 RNA expression–survival associations across cancer types. High ARR3 expression shows unfavorable associations in KIRC, THCA, COAD, KICH and LGG, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARR3 RNA expression.
This table summarizes ARR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ARR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARR3 shows lower tumor expression in BRCA and KIRP and higher tumor expression in LIHC, STAD, CHOL and PRAD. The LIHC box plot shows higher ARR3 RNA expression in tumor versus normal tissue (log2 FC = +0.211, t-test p < 0.001).
This table shows molecular features associated with ARR3 in patient tissues and cancer cell lines. In patient samples, ARR3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
